The State of Personalized Medicine: The Role of Biomarkers

By Dr. Evian Gordon | February 13, 2012

(Edi­tor’s Note: this is Part 1 of the new 3‑part series writ­ten by Dr. Evian Gor­don draw­ing from his par­tic­i­pa­tion at the Per­son­al­ized Med­i­cine World Con­gress on Jan­u­ary, 23, 2012 at Stan­ford Uni­ver­si­ty.) On aver­age, the med­ica­tions pre­scribed for brain-relat­ed con­di­tions ben­e­fit approx­i­mate­ly 50% of patients. But which 50%? Per­son­al­ized Med­i­cine seeks to move away from…

Read More

New Series on Personalized Medicine and the Brain (PMWC 2012)

By Alvaro Fernandez | February 10, 2012

“On aver­age, the med­ica­tions pre­scribed for brain-relat­ed con­di­tions ben­e­fit approx­i­mate­ly 50% of patients.  But which 50%?.” “We need unam­bigu­ous bio­mark­ers that are clin­i­cal­ly rel­e­vant and scal­able at rea­son­able cost. They already exist in Can­cer.   But they do not yet exist in the Brain.” What may change that?

Read More